{"title":"Effectiveness and Toxicity Burden of Pembrolizumab in Combination With Neoadjuvant Chemotherapy for Stage II/III Triple Negative Breast Cancer: A Real-World Analysis From Alberta, Canada.","authors":"Kaiden Jobin, Malek B Hannouf, Shiva Bahmanyar, Ammara Naseer, Agnes Ho, Sasha Lupichuk","doi":"10.1097/COC.0000000000001399","DOIUrl":"https://doi.org/10.1097/COC.0000000000001399","url":null,"abstract":"<p><strong>Objectives: </strong>The KEYNOTE-522 trial demonstrated improved pathologic complete response (pCR) and long-term survival outcomes by adding pembrolizumab to neoadjuvant anthracycline and taxane (A-T) plus carboplatin in patients with stage II/III triple-negative breast cancer (TNBC). We evaluated early effectiveness and toxicity burden of adding pembrolizumab and carboplatin to neoadjuvant A-T in patients with stage II/III TNBC.</p><p><strong>Methods: </strong>We included all patients in Alberta with stage II/III TNBC from November 2020 to November 2023, treated with either neoadjuvant A-T or the KEYNOTE-522 regimen, and who underwent surgical resection by June 1, 2024. Our primary outcome was pCR, while secondary outcomes included rates of breast-conserving surgery (BCS), axillary lymph node dissection (ALND), toxicity burden during the neoadjuvant phase, and receipt/type of adjuvant therapy. Propensity score matching (PSM) was conducted to account for baseline differences between groups.</p><p><strong>Results: </strong>A total of 248 patients were included (110 A-T and 138 KEYNOTE-522). Before PSM, the KEYNOTE-522 group had higher rates of pCR (64% vs. 32%; P<0.001) and BCS (57% vs. 42%; P=0.022) with lower rates of ALND (15% vs. 40%; P<0.001). The KEYNOTE-522 group had more emergency department visits (47% vs. 31%, P=0.010) and hospitalizations (23% vs. 6%, P<0.001). After PSM, baseline characteristics between groups were balanced, and differences in effectiveness and toxicity burden outcomes persisted. Within the KEYNOTE-522 group, 70% had postoperative pembrolizumab.</p><p><strong>Conclusions: </strong>Proportions of pCR and BCS were higher, and ALND lower, in KEYNOTE-522 treated patients with stage II/III TNBC, even after PSM. Future evaluation is needed to determine the real-world impact of the KEYNOTE-522 regimen on recurrence and survival.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of Metastatic Spine Score on Optimizing Enrollment Selectivity on a Multicenter Phase Two Randomized Controlled Trial.","authors":"Shearwood McClelland","doi":"10.1097/COC.0000000000001403","DOIUrl":"https://doi.org/10.1097/COC.0000000000001403","url":null,"abstract":"<p><strong>Objectives: </strong>A key barrier to successful trial completion is that enrolled patients do not reach the trial's primary endpoint timeframe. This study examines the impact of a heuristic algorithm on screening patients who are otherwise at high risk for primary endpoint failure in a trial that has recently completed enrollment.</p><p><strong>Methods: </strong>The Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN) multicenter Phase II randomized controlled trial examines the impact of radiation therapy on pain freedom in metastatic spine disease, with a primary endpoint of pain freedom at 3 months post-treatment. The rate of enrollment failure due to predicted inadequate prognosis (<3 mo) was compared before versus after implementation of the Metastatic Spine Score to assess the impact of this algorithm on trial enrollment.</p><p><strong>Results: </strong>A total of 136 patients were evaluated for trial enrollment. The first 64 patients were evaluated before the implementation of the Metastatic Spine Score, of whom 1 (2%) was excluded from enrollment due to an inadequate prognosis. The final 72 patients were evaluated after implementation of the Metastatic Spine Score; 15 patients (21%) were excluded from enrollment due to an inadequate prognosis. This difference in exclusion rate was statistically significant (P=0.0003).</p><p><strong>Conclusions: </strong>In conclusion, the implementation of a heuristic algorithm during clinical trial enrollment had a significant impact on the prohibition of enrollment of patients at increased risk of primary endpoint failure. These results serve as a reminder of the importance of objectively quantifying prognosis and its impact on the risk of primary endpoint failure.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Colorectal Cancer Incidence in the US Versus Canada, Among Individuals Aged 45 to 49 Years, Following US Expansion of Screening Eligibility.","authors":"Omar Abdel-Rahman, Sunita Ghosh","doi":"10.1097/COC.0000000000001402","DOIUrl":"https://doi.org/10.1097/COC.0000000000001402","url":null,"abstract":"<p><strong>Objectives: </strong>To examine the differences in colorectal cancer (CRC) incidence between the US and Canada, among individuals aged 45 to 49 years, following expansion of screening eligibility in the US.</p><p><strong>Methods: </strong>This is an ecological analysis based on publicly available data for CRC incidence in the US and Canada. US data were based on the US Cancer Statistics Public Use Research Database, while the Canadian data were based on Statistics Canada tables (which represented all Canadian jurisdictions except for Nova Scotia). Descriptive analyses for cancer incidence rates per 100,000 among individuals aged 45 to 49 years were performed for Canada versus the US, with stratification performed for age group, sex, and subsite. Subsequently, a difference-in-differences (DiD) analysis was performed to further examine the differences between the US and Canada.</p><p><strong>Results: </strong>Colorectal cancer rates per 100,000 (2016 to 2023) for individuals aged 45 to 49 years increased in Canada from 30.6 (2016) to 34 (2023), while in the US, rates increased from 34.9 (2016) to 53.1 (2023). For the US data, when calculating the percentage of localized disease out of all patients with known stages, this increased from 28.5% in 2016 to 40.8% in 2023. Furthermore, comparing US versus Canadian data and using pre- versus postexpansion policy means in both countries, DiD was 12.85 (95% CI: 10.13-15.57, P<0.001).</p><p><strong>Conclusions: </strong>Expansion of CRC screening eligibility in the US was associated with a significant increase in reported CRC incidence in the US versus Canada, among individuals 45 to 49 years old, which was principally driven by increasing rates of localized-stage diagnoses.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abigail Lin, Samantha R Spierling Bagsic, Cammie H Nguyen, Emily C Soriano, Shane Mesko, Adelaide L Fortmann, Athena Philis-Tsimikas, Thomas A Buchholz
{"title":"Racial, Ethnic, and Regional Influences on National Patterns of Mammographic Screening.","authors":"Abigail Lin, Samantha R Spierling Bagsic, Cammie H Nguyen, Emily C Soriano, Shane Mesko, Adelaide L Fortmann, Athena Philis-Tsimikas, Thomas A Buchholz","doi":"10.1097/COC.0000000000001400","DOIUrl":"https://doi.org/10.1097/COC.0000000000001400","url":null,"abstract":"<p><strong>Objectives: </strong>We sought to evaluate whether there were clinically significant disparities in screening mammography rates according to race, ethnicity, and United States geographic region in patients with access to health care systems.</p><p><strong>Methods: </strong>We queried the Cosmos Epic national database to ascertain mammographic screening rates for women aged 50 to 65 who had 1 or more ambulatory encounters with a primary care physician between November 9, 2020, and November 8, 2023. Patients with a previous breast cancer and those with missing race or ethnicity data were excluded.</p><p><strong>Results: </strong>The overall mammographic screening rate was 63.8% in the 7,837,164 individuals who met study criteria. There were no clinically meaningful differences in screening according to race. However, screening was less frequent in those with Hispanic ethnicity versus non-Hispanic (58.9% vs. 64.3%, P<0.001). Rates also varied according to region, with the lowest rates in the West (55.5%, P<0.001). Screening rates for Black and White groups were within 5% of one another in all 4 regions. With respect to ethnicity, the South was the only region where the Hispanic population rate had a lower rate over 5% (61.8% vs. 55.7%, P<0.001).</p><p><strong>Conclusions: </strong>Many patients receiving health care in the US do not receive recommended mammogram screening, but there were no clinically significant differences by race. Lower rates were noted in Hispanic populations, particularly in the South. Targeted educational and community outreach efforts in this region are warranted.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety and Efficacy of 2-Fraction Stereotactic Radiosurgery for Brain Metastases.","authors":"Shearwood McClelland","doi":"10.1097/COC.0000000000001401","DOIUrl":"https://doi.org/10.1097/COC.0000000000001401","url":null,"abstract":"<p><strong>Objectives: </strong>Stereotactic radiosurgery (SRS) is the predominant modality for treating brain metastases. Fractionated SRS has benefits of improved local control and decreased morbidity over single-fraction SRS for larger lesions, typically performed in 3 to 5 fractions. This series is the first report of 2-fraction SRS for brain metastases.</p><p><strong>Methods: </strong>Patients at a National Cancer Institute-designated cancer center with metastatic brain disease deemed suitable for fractionated SRS from August 2025 to September 2026 were included. Constraints used were the Timmerman 2-fraction tables for organs-at-risk, and brain-planning target volume (PTV) V20 Gy <20 cm3 to minimize radiation necrosis risk. SRS was performed with mask-based immobilization using either Gamma Knife or a linear accelerator.</p><p><strong>Results: </strong>A total of 65 lesions in 15 patients were treated to 24 Gy in 2-fraction SRS (56 untreated brain metastases, 3 planned preoperative treatment, 6 for postoperative treatment). One lesion (1.8%) developed symptomatic radiation necrosis; another lesion (2.4 cm) required subsequent unplanned operative intervention. Local control was achieved in 92% of lesions with a minimum of 10 months of follow-up.</p><p><strong>Conclusions: </strong>This study provides the first evidence supporting 2-fraction SRS for brain metastases as a safe and efficacious alternative to the longer 3-fraction and 5-fraction regimens. The low radiation necrosis rate (<2%) utilizing the brain-PTV V20 <20 cm3 constraint is a novel aspect of this series, demonstrating that 2-fraction SRS can be performed with minimal morbidity. As the most expedient fractionated SRS regimen, 2-fraction treatment yields several advantages over longer regimens.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ricaurte Crespo-Trevino, Justin Choe, Rebecca Hibbert, David Toro-Tobon, Marius Stan, M Regina Castro
{"title":"Metastasis of Nonthyroidal Malignancies to the Thyroid Gland: A 15-Year Institutional Experience.","authors":"Ricaurte Crespo-Trevino, Justin Choe, Rebecca Hibbert, David Toro-Tobon, Marius Stan, M Regina Castro","doi":"10.1097/COC.0000000000001386","DOIUrl":"https://doi.org/10.1097/COC.0000000000001386","url":null,"abstract":"<p><strong>Objectives: </strong>Metastasis to the thyroid gland (MTT) is uncommon, and its presentation, diagnosis, and management remain incompletely characterized. We described a contemporary institutional cohort and examined detection, diagnostic evaluation, treatment, and survival after MTT diagnosis.</p><p><strong>Methods: </strong>We conducted a retrospective descriptive cohort study of patients with pathologically confirmed MTT who were evaluated at the Mayo Clinic in Rochester, Minnesota, from 2010 through 2025. Clinical, imaging, cytologic, pathologic, treatment, and outcome data were abstracted from the electronic health record. Survival was estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>Among 42 patients, the most common primary malignancies were kidney (40.5%) and lung (23.8%). MTT was detected incidentally on staging or surveillance imaging in 66.7% and was symptomatic in 23.8%. The median interval from primary cancer diagnosis to MTT was 3.67 years and was longer for kidney cancer (8.7 y) than lung cancer (0.94 y). Most lesions were unifocal (81.0%); common ultrasound features were solid composition (50.0%) and hypoechogenicity (47.6%), but findings were nonspecific. Among 23 patients evaluated with a single fine-needle aspiration (FNA) before diagnosis, metastasis was confirmed on the first procedure in 56.5% of cases. Eighteen patients underwent surgery. The median overall survival after MTT diagnosis was ∼1.75 years; outcomes differed by surgical status, although treatment selection and disease extent preclude causal interpretation.</p><p><strong>Conclusions: </strong>MTT should be considered in patients with a new thyroid lesion and a history of malignancy. Tissue diagnosis may require repeat FNA, core-needle biopsy, and immunohistochemistry. Management should be individualized based on symptoms, primary tumor biology, extent of systemic disease, and goals of care.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maria A Lasprilla-Pallares, Madison Garza, Misty Walker, Carla Ponce, Shearwood McClelland
{"title":"Assessment of Individual and Familial Financial Toxicity Using the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT): Early Findings From the Navigator-Assisted Hypofractionation (NAVAH) Trial Expansion to Hispanic-American Breast Cancer Patients.","authors":"Maria A Lasprilla-Pallares, Madison Garza, Misty Walker, Carla Ponce, Shearwood McClelland","doi":"10.1097/COC.0000000000001397","DOIUrl":"https://doi.org/10.1097/COC.0000000000001397","url":null,"abstract":"<p><strong>Objectives: </strong>Hispanic-American populations face a high and growing burden of cancer and health disparities. Financial toxicity (FT) describes the economic distress experienced by cancer patients during diagnosis/treatment; familial financial toxicity (FFT) describes the financial distress experienced by families adapting to the economic challenges of cancer. This study assesses FT/FFT among Hispanic-American breast cancer patients enrolled in the Navigator-Assisted Hypofractionation (NAVAH) Phase I clinical trial.</p><p><strong>Methods: </strong>Six patients undergoing radiation therapy were assessed using the validated Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) instrument. The mean score of the first 11 questions was used to classify individual FT as grade 0 (absent), grade 1 (mild), grade 2 (moderate), or grade 3 (severe), with lower scores indicating greater FT. Question 12 (Q12) was evaluated separately to measure FFT, with scores ranging from 0 to 4. An exploratory linear regression analysis examined the relationship between individual FT and FFT.</p><p><strong>Results: </strong>All patients reported mild or moderate individual FT, with Q12 scores ranging from 2 to 4. An exploratory linear regression analysis demonstrated a strong inverse association between individual COST-FACIT scores and Q12 scores (r=-0.891, P=0.01). Lower COST-FACIT scores (indicating greater individual FT) were associated with higher Q12 scores, indicating greater perceived familial financial hardship.</p><p><strong>Conclusions: </strong>These findings suggest a strong association between individual and familial FT among Hispanic-American breast cancer patients. Assessing familial FT may help identify the broader economic impact of cancer treatment and inform supportive interventions addressing financial hardship among patients and their families.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN): Time to Treatment Outcomes From a Multicenter Phase II Randomized Controlled Trial.","authors":"Shearwood McClelland, Louisa Onyewadume, Momina Anwar","doi":"10.1097/COC.0000000000001396","DOIUrl":"https://doi.org/10.1097/COC.0000000000001396","url":null,"abstract":"<p><strong>Objectives: </strong>For treatment of spine metastases, stereotactic body radiation therapy (SBRT) has been proven to yield improved local control durability compared with external beam radiation therapy (EBRT) despite requiring more complexity in treatment planning. The time to initiation of treatment is an important consideration in this patient population, yet has rarely been assessed. We present our findings regarding this aspect of care from the Spine Patient Optimal Radiosurgery Treatment for Symptomatic MEtastatic Neoplasms (SPORTSMEN) phase II multicenter randomized controlled trial.</p><p><strong>Methods: </strong>In the SPORTSMEN trial, patients with symptomatic spine metastases are randomized to SBRT (24 Gy in 2 fractions, 19 Gy in 1 fraction) versus EBRT (8 Gy in 1 fraction). The primary trial endpoint is 3-month pain freedom, using the Brief Pain Inventory. The time from patient randomization to treatment initiation was assessed and compared between SBRT and EBRT.</p><p><strong>Results: </strong>Of the first 26 patients treated in the study, 19 received SBRT, and 7 received EBRT. The mean time from randomization to treatment (TRT) for EBRT was 3.7 days (SD±2.36) versus 10.3 days (SD±5.79) for SBRT. This difference in TRT of 6.6 days was statistically significant (P=0.0079).</p><p><strong>Conclusion: </strong>Level I evidence indicates that compared with EBRT, patients with symptomatic spine metastatic disease receiving SBRT experience an ∼1-week delay in starting treatment. This finding should play a role in informed consent discussions with patients, particularly those who are already symptomatic from their metastatic disease.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandra Stump, Momina Anwar, Caleb Seekins, Shearwood McClelland
{"title":"Pain Relief Without Financial Relief: Individual and Familial Financial Toxicity After Radiation Therapy for Spine Metastases in the Phase II SPORTSMEN Trial.","authors":"Alexandra Stump, Momina Anwar, Caleb Seekins, Shearwood McClelland","doi":"10.1097/COC.0000000000001398","DOIUrl":"https://doi.org/10.1097/COC.0000000000001398","url":null,"abstract":"<p><strong>Objectives: </strong>Prospective data on patient-reported financial toxicity (FT) during radiation therapy for spine metastases are limited. This secondary analysis of the SPORTSMEN trial (NCT05617716) characterized FT and quality of life, including changes 3 months after treatment.</p><p><strong>Methods: </strong>SPORTSMEN is a phase II trial randomizing patients with symptomatic spine metastases to SBRT (24 Gy/2 fractions or 19 Gy/1 fraction) or conventional EBRT (8 Gy/1 fraction). FT was measured with the COST-FACIT (lower scores indicate greater FT) and graded 0 (none) to 3 (severe); item 12 assessed familial hardship. Quality of life was measured with the EQ-5D-5L (higher scores indicate worse function) and EQ Visual Analog Scale (VAS). Analyses used Spearman correlation and the exact Wilcoxon signed-rank test.</p><p><strong>Results: </strong>Of 18 enrolled patients since 2025, 15 completed baseline COST-FACIT and 17 completed EQ-5D-5L. Eight (53%) had grade 1 to 2 FT. All patients with FT reported familial financial hardship, which correlated with FT grade (ρ=0.67, P=0.007). Pain was the most impaired domain (mean: 3.9, 71% severe or extreme). Among 7 patients with 3-month data, pain decreased from 4.3 to 2.3 (P=0.0625), EQ VAS rose from 44 to 64 (P=0.34), and FT increased from 2/7 patients to 5/7 patients.</p><p><strong>Conclusions: </strong>More than half of patients had FT before radiation therapy, closely tied to familial hardship. Although pain and self-rated health improved after treatment, FT did not. Financial screening and support for patients and families should begin at diagnosis and continue after treatment.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety and Efficacy of Reduced-Dose Stereotactic Radiosurgery Dose Administered With Concomitant Central Nervous System-Penetrant Systemic Therapy for Brain Metastases.","authors":"Shearwood McClelland","doi":"10.1097/COC.0000000000001395","DOIUrl":"https://doi.org/10.1097/COC.0000000000001395","url":null,"abstract":"<p><strong>Objectives: </strong>The reported rate of symptomatic radiation necrosis (SRN) in patients with brain metastases treated with immune checkpoint inhibitor therapy and concomitant single-fraction stereotactic radiosurgery (SRS) is as high as 20%. Previous work has piloted reduced-dose SRS as a potential solution. We present our experience with reduced-dose SRS to further assess its safety and efficacy for this patient population.</p><p><strong>Methods: </strong>Patients receiving SRS within 30 days of CNS-penetrant systemic therapy for brain metastases of 0 to 2 cm maximum diameter on MRI were treated with 18 Gy SRS and prospectively followed. The rates of 6-month local control and 6-month SRN were assessed.</p><p><strong>Results: </strong>Fifty-nine brain metastases were treated in 17 patients. The most common systemic therapy used was single-agent atezolizumab (25% of lesions) and single-agent pembrolizumab (19% of lesions). The most common primary tumors were small cell lung cancer, renal cell carcinoma, and lung adenocarcinoma (68% of lesions). The 6-month local control rate was 96%, with no 6-month SRN.</p><p><strong>Conclusions: </strong>In the largest series examining reduced-dose SRS with concomitant CNS-penetrant systemic therapy, our findings confirm previous reports of the safety and efficacy of single-fraction 18 Gy SRS for brain metastases with maximum diameter 0 to 2 cm receiving therapy within 30 days of SRS. The excellent local control with minimal SRN at this dose supports 18 Gy for patients with brain metastases 2 cm or smaller receiving CNS-penetrant systemic therapy as preferable to the traditionally higher SRS doses, which have represented the standard of care, while remaining preferable to systemic therapy alone.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}